Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for the treatment of multiple solid tumor indications. The company's core technology is the CELx diagnostic platform, which measures real-time cell signaling responses in living tumor cells to identify functional cellular abnormalities and match patients with appropriate targeted treatments. Celcuity's lead therapeutic candidate is gedatolisib, a highly differentiated pan-PI3K and mTORC1/2 inhibitor designed to comprehensively blockade the PAM pathway, a critical biological driver in various cancers. Gedatolisib is currently undergoing late-stage clinical trials, including the Phase 3 VIKTORIA studies for patients with HR+/HER2- advanced breast cancer, as well as early-stage trials for metastatic castration-resistant prostate cancer. Headquartered in Minneapolis, Minnesota, the company operates primarily in the United States and focuses its research and development efforts on addressing unmet medical needs in oncology.
